P53 Gene Mutations in Chronic Myelogenous Leukemia Medullary and Extramedullary Blast Crisis

References

• Yin Y., Tainsky M. A., Bischoff F. Z., Strong L. C., Wahl G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–948
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E., Resnitzky P., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345–347
   PubMed Web of Science ®Google Scholar
• Soddu S., Blandino G., Citro G., Scardigli R., Piaggio G., Ferber A., Calabretta B., Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994; 83: 2230–2237
   PubMed Web of Science ®Google Scholar
• El-Deity W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genetics 1992; 1: 45–49
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. Mdm-2 expression is induced by wild-type p53 activity. EMBO J. 1993; 12: 461–468
   PubMed Web of Science ®Google Scholar
• Kastan M. B., Zhan Q., El-Deity W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587–597
   PubMed Web of Science ®Google Scholar
• El-Deity W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator for p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyormarsi K., Elledge S. J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinase. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 1992; 89: 12028–12032
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sindranski D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412–2421
   PubMed Web of Science ®Google Scholar
• Daley G. Q., van Etten R. A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Advani S. H., Benchimol S., Cline M. J. Alterations of the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc. Natl. Acad. Sci. USA 1989; 86: 6783–6787
   PubMed Web of Science ®Google Scholar
• Kelman Z., Prokocimer M., Peller S., Kahn Y., Rechavi G., Manor Y., Cohen A., Rotter V. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74: 2318–2324
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S. L., Goldman J., Snyder D., Foti A., Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991; 87: 2042–2047
   PubMed Web of Science ®Google Scholar
• Feinstein E., Cimino G., Gale R. P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA 1991; 88: 6293–6297
   PubMed Web of Science ®Google Scholar
• Neubauer A., He M., Schmidt C. A., Huhn D., Liu E. T. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 1993; 7: 593–600
   PubMed Web of Science ®Google Scholar
• Gaidano G., Serra A., Guerrasio A., Rege-Cambrin G., Mazza U., Saglio G. Genetic analysis of p53 and RBI tumor-suppressor genes in blast crisis of chronic myeloid leukemia. Ann. Hentatol. 1994; 68: 3–7
   PubMed Web of Science ®Google Scholar
• Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 5520–5525
   PubMed Web of Science ®Google Scholar
• Marasca R., Longo G., Luppi M., Barozzi P., Torelli G. Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia. Leuk. Lymph. 1994; 16: 171–175
   PubMed Web of Science ®Google Scholar
• Mashal R., Shtalrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J., Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Hemandez A., Hernandez P., Corral L., Muniz A., Alaez C., Espinosa E., Fernandez O., Martinez G. P53 gene rearrangements in chronic myelocytic leukemia. Ann. Hematol. 1993; 66: 81–83
   PubMed Web of Science ®Google Scholar
• Foti A., Ahuja H. G., Allen S. L., Koduru P., Schuster M. W., Schulman P., Bar-Eli M., Cline M. J. Correlation between molecular and clinical events in the evolution of chronic myelocityc leukemia to blast crisis. Blood 1991; 77: 2441–2444
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Toguchida J., Yandell D. W., Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res. 1992; 52: 6588–6593
   PubMed Web of Science ®Google Scholar
• Mori N., Wada M., Yokota J., Terada M., Okada M., Teramura M., Masuda M., Hoshino S., Motoji T., Oshimi K., Mizoguchi H. Mutations of the p53 tumor suppressor gene in haematologic neoplasms. Br. J. Haemat. 1992; 81: 235–240
   PubMed Web of Science ®Google Scholar
• Schutte J., Opalka B., Becher R., Bardenheuer W., Szymanski S., Lux A., Seeber S. Analysis of the p53 gene in patients with isochromosome 17q and Phl-positive or negative myeloid leukemia. Leukemia Res. 1993; 17: 533–539
   PubMed Web of Science ®Google Scholar
• Nakagawa H., Fujii H., Nakai H., Inazawa J., Misawa S. Myelomonocytic crisis with t(5;17) and a p53 mutation in a patient with chronic myelogenous leukemia. Am. J. Hematol. 1994; 45: 335–340
   PubMed Web of Science ®Google Scholar
• Tanaka K., Takauchi K., Takechi M., Dohy H., Kamada N. Chronic myelocytic leukemia with myeloblastoma has higher frequency of RAS oncogene mutation. Leukemia Res. 1992; 16: 947
   PubMed Web of Science ®Google Scholar
• Caron de Frommentel C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer 1992; 4: 1–15
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar